Contact

Please use this form to send email to PR contact of this press release:
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

TO:

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.
	SEND EMAIL